司库奇尤单抗在中重度斑块状银屑病真实世界人群中显示持续的治疗留存、有效性和安全性:SERENA 研究中期分析长期结果
SERENA 是一项在 438 个中心、19 个国家开展的大型纵向观察性研究,纳入接受司库奇尤单抗治疗至少 16 周的中重度斑块状银屑病成人患者 1756 例。中期分析显示,研究第 1、2、3 年的治疗留存率分别为 88.0%、76.4% 和 60.5%,平均 PASI 从治疗开始时的 21.0 降至基线 2.6,并在第 1、2、3 年维持在较低水平。安全性特征与已知一致,未报告新的安全性信号。
要点
- 研究第 1、2、3 年司库奇尤单抗治疗留存率分别为 88.0%、76.4%、60.5%。
- 648 例停药患者中,最常见原因为疗效不足(42.6%)和不良事件(17.4%)。
- 平均 PASI 从治疗开始时的 21.0 降至基线 2.6,第 1、2、3 年分别为 2.3、1.9、1.9。
核心结论
- 在 SERENA 研究观察的真实世界银屑病患者中,司库奇尤单抗随访至 3 年显示高治疗留存率、持续有效性和良好的安全性。
研究设计与样本
- SERENA(CAIN457A3403)是一项大型、正在进行的纵向观察性研究,在 438 个中心、19 个国家开展,预期持续时间最长 5 年。
- 研究对象为接受司库奇尤单抗治疗至少 16 周后入组的中重度斑块状银屑病、银屑病关节炎和强直性脊柱炎成人患者。
- 本次中期分析纳入 2016 年 10 月至 2018 年 10 月入组并观察至少 2 年的银屑病患者,共 1756 例(男性 67.3%),平均年龄 48.4 岁,平均体重指数 28.8 kg/m2。
主要发现
- 研究第 1、2、3 年的司库奇尤单抗治疗留存率分别为 88.0%、76.4% 和 60.5%。
- 648 例停药患者中,停药原因包括疗效不足(42.6%)、不良事件(17.4%)、医生决定(12.2%)和受试者决定(11.6%)。
- 治疗开始时平均±标准差绝对 PASI 为 21.0±13.0(n=1564),基线时平均±标准差 PASI 降至 2.6±4.8,第 1 年(2.3±4.3)、第 2 年(1.9±3.6)和第 3 年(1.9±3.5)维持较低水平。
- 安全性特征与已知一致,未报告新的安全性信号;炎症性肠病发生率 0.3%(发生率[IR]:0.15),念珠菌感染发生率 3.1%(IR:1.43),主要不良心血管事件(MACE)发生率 0.9%(IR:0.37)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Randomized controlled trials of secukinumab have shown sustained efficacy and a favourable safety profile in multiple manifestations of psoriatic disease. OBJECTIVES: To assess the long-term, real-world retention, effectiveness and safety of secukinumab in routine clinical practice for the treatment of moderate-to-severe plaque-type psoriasis (PsO). METHODS: SERENA (CAIN457A3403) is a large, ongoing, longitudinal, observational study conducted at 438 sites and 19 countries for an expected duration of up to 5 years in adult patients with moderate-to-severe PsO, psoriatic arthritis and ankylosing spondylitis. Patients received ≥16 weeks of secukinumab treatment before enrolment. This interim analysis presents data from PsO patients, who were enrolled in the study between October-2016 and October-2018 and were observed for ≥2 years. RESULTS: In total, 1756 patients (67.3% male) with a mean age of 48.4 years and body mass index of 28.8 kg/m2 were included in the analysis. The secukinumab treatment retention rates after 1, 2 and 3 years in the study were 88.0%, 76.4% and 60.5%, respectively. Of the 648 patients who discontinued the study, the most common reasons included lack of efficacy (42.6%), adverse event (17.4%), physician decision (12.2%) and subject decision (11.6%). Mean ± SD absolute PASI was 21.0 ± 13.0 at the start of treatment (n = 1,564). At baseline, the mean ± SD PASI score reduced to 2.6 ± 4.8 and remained low at Year 1 (2.3 ± 4.3), Year 2 (1.9 ± 3.6) and Year 3 (1.9 ± 3.5). The safety profile of secukinumab during the SERENA study was consistent with its known safety profile, with no new safety signals reported. Particularly, low rates of inflammatory bowel disease (0.3%; Incidence Rate [IR]:0.15), candida infections (3.1%; IR:1.43) and MACE (0.9%; IR:0.37) were observed. CONCLUSIONS: Secukinumab showed high treatment persistence, sustained effectiveness and a favourable safety profile up to 3 years of follow-up in the real-world population of PsO patients observed in SERENA.
引用
- Augustin M, Sator PG, von Kiedrowski R, et al. Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study. J Eur Acad Dermatol Venereol. 2022. PMID: 35696305. doi:10.1111/jdv.18329
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。